NCT06422546Recruiting
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers After Three Weeks of Osimertinib Targeted Therapy in Chinese Patients With Stage IIIB ,IIIC ,or IV Metastatic or Recurrent Non Squamous EGFR-positive Non-small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
A prospective ,multicenter ,non-interventional ,real-world study observing changes in molecular markers after three weeks of osimertinib targeted therapy in EGFRm NSCLC
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 950 (estimated)
- First submitted
- 15 May 2024
- Start date
- 28 Dec 2021
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Beijing Cancer Prevention & Treatment Society
- Diseases
- Lung cancer
- NCT number
- NCT06422546
What you commit to
- Study type: Observational
- Planned participants: 950
- From 28 Dec 2021 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Refusal to receive subsequent treatment with osimertinib .
Other illness
- Any condition that ,in the investigator's judgment ,could interfere with study procedures or confound outcome assessment .
Lab values
- Baseline blood EGFR mutation status not confirmed by the central laboratory .
Other
- Inability to provide plasma samples at baseline .
Who the study is looking for
- Male or female,age ≥18 years.
- Newly diagnosed,histologically confirmed,and classified as stage IIIB,IIIC,IV or recurrent NSCLC which are not amenable to curative surgery or radiotherapy .
- No prior systemic antitumor therapy, including EGFR -TKIs or immunotherapy .
- Presence of an EGFR mutation confirmed by a local laboratory in blood or tissue samples .
- Adequate blood samples available for molecular testing .
- Provision of written informed consent .
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cancer Hospital Chinese Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.